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This article refers to ‘Upgrades from a previous device
compared to de novo cardiac resynchronization therapy
in the European Society of Cardiology CRT Survey II’
by C.M. Linde et al., published in this issue on pages
1457–1468.
Cardiac resynchronization therapy (CRT) is an effective electrical
treatment for selected patients with heart failure and wide QRS
interval that, following the pioneering experiences performed in
France around 20 years ago, obtained full development and clinical
validation, moving from a compassionate treatment used in a
few cases as a ‘last resort’ option, to a treatment tested and
validated in randomized controlled trials (RCTs), both in the setting
of moderate–severe heart failure and of mild heart failure with
reduced ejection fraction.1 The implementation of CRT across
Europe is variable, fluctuating considerably in implant rates within
and across countries, as a result of the influence of different types of
health care systems, as well as of different economic, demographic
and cultural contexts.2,3
As a result of the RCTs performed in the last 15 years, that over-
all involved more than 10 000 patients,4 CRT has been included in
consensus guidelines as a treatment with proven efficacy in improv-
ing symptoms and outcomes in appropriately selected patients. The
implant of a CRT system with a pacemaker (CRT-P) or a defibrilla-
tor (CRT-D) may be indicated also in patients previously implanted
with a pacemaker (PM) or an implantable cardioverter-defibrillator
(ICD), and this constitutes what is normally considered as an
‘upgrade procedure’. Only in the last 5–6 years has an upgrade to
CRT-P or CRT-D been included among the recommendations for
CRT delivered by European or American societies.1 This reflects
the relative paucity of literature on upgrade to CRT and the lack
of RCTs: a search on PubMed showed that in the last 5 years only
73 articles were published on CRT and upgrade, while during the
same period 3350 papers were published, in general, on CRT.
In this issue of the Journal, Linde et al.5 report the results of the
European Society of Cardiology CRT Survey II focusing on baseline
patient characteristics, details of implantation procedures and
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. related short-term complications in patients undergoing upgrading
to CRT-P or CRT-D in comparison to patients who underwent
de novo implantation with a CRT device. The data were collected
across 42 European Society of Cardiology countries between
October 2015 and December 2016. Out of 11 088 patients, ∼23%
were upgraded from a previous PM or ICD while ∼77% underwent
de novo implantation. Although upgraded patients compared to
patients with de novo CRT implant had older age and more
advanced heart failure, CRT implantation procedures were equally
successful and had similar in-hospital complication rates.
The authors are to be commended for having provided a
contemporary overview of upgrading procedures to CRT across
Europe. However, some considerations are needed in order to
realise that such analyses are of primary importance and need to
be expanded to larger cohorts with longer follow-up periods. In
this CRT Survey II, the patients were discharged after a median
hospital stay of 3 days and the study plan did not include follow-up
data after discharge. A focus on longer follow-up periods, up to
6 months–1 year, is necessary in order to capture the occurrence
of post-discharge major complications, most of which are reported
in Figure 1, with the indication of the most vulnerable periods.6–11
The majority of CRT implantations (82%) were performed in
either university or teaching hospitals and this may condition the
rate and type of complications. Analysing the Danish National reg-
istry on cardiac implantable electronic device procedures, Kirkfeldt
et al.10 found that centres with <750 annual procedures and low
volume operators (<50 annual procedures) had higher complica-
tion rates overall. In a series of reports, upgrade procedures appear
to be associated with a higher burden of complications as com-
pared to de novo implants ranging from 6.8% to 20.9%.9
Probably the most feared complication of upgrades to CRT is
device-related infection,9 due to the high impact on associated mor-
tality, morbidity and costs for health care systems, and the only
effective approach to manage this issue is complete removal of all
the implanted hardware through percutaneous lead extraction.12
Notably, this complication usually occurs weeks or months after
the procedure and the presence of a delay in defining the correct
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Figure 1 Incidence and usual most vulnerable periods for complications of cardiac resynchronization implants or upgrades.6–11 CIED, cardiac
implantable electronic device; CS-diss, coronary sinus dissection; d, days; fup, follow-up; mo, months; unsuc, unsuccessful; yr, years.
diagnosis is common. This means that this type of complication
could not be a topic of investigation in this survey focused on
pre-discharge events. However, when planning an upgrade proce-
dure, the risk of device infection has to be considered since both
the procedure type and the involved device (CRT) are indepen-
dent risk factors.8 Despite the relevant improvements in tools and
techniques leading to an impressive decrease in procedure-related
complications,13 1-year mortality ranges between 10% to 20%.14,15
In this regard, it is relevant to note that the same risk factors for
development of device infection are associated with increased risk
of post-extraction mortality, leading to consideration that preven-
tion of infection is of paramount importance by carefully evaluating
upgrade procedures in high-risk patients and by adopting all the
precautions including all the procedural factors.8,16 Hopefully, the
results of the ongoing WRAP-IT trial will provide important data
on this relevant topic.16
Additional clinical points can be considered. The upgrade from a
PM to a CRT-D is technically complex, and at least in non-ischaemic
cardiomyopathy should occur less frequently in the future con-
sidering the mean age of patients with a previous implanted PM
who are candidates for upgrade and the results of the DANISH
trial.4,17 The issue of atrioventricular node ablation in patients
with atrial fibrillation who receive an upgrade to CRT is another
important point, and it should be stressed that atrioventric-
ular node ablation is crucial for achieving the full benefit of
CRT (by ensuring >95% ventricular pacing) even if no RCT val-
idated the strategy of atrioventricular node ablation combined
with CRT.18
The data reported by Linde et al.5 clearly show that patients
who are candidates for upgrade to CRT have a different profile














































.. prevalence of coronary artery disease, valvular heart disease,
chronic kidney disease, anaemia, and atrial fibrillation. Most of
these factors have been found to be associated with a worse
response to CRT and a worse outcome,17,19,20 leading to an
important clinical question: ‘What is the long-term outcome of
these patients?’. Upgrade to CRT has never been the subject of
a randomized clinical study but a recent systematic review and
meta-analysis identified a total of 16 reports including 489 568
CRT recipients, of whom 21 363 patients underwent an upgrade
procedure. The results included both unadjusted and adjusted
estimates, but in general found similar risks for all-cause mortality
and heart failure hospitalizations for CRT upgrade vs. de novo CRT
implant, also with similar improvement in functional capacity and
similar degree of left ventricular reverse remodelling.11
Observational studies or surveys like the European CRT Sur-
vey II are extremely interesting when a procedure, like upgrades,
has not been covered by RCTs, because of lack of interest from
the industry. The challenge in the future will be to have follow-up
data as part of the quality control that every health care sys-
tem should provide, in order to upgrade outcome research in
the field, in line with the virtuous circle of Health Technology
Assessment.21
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